Risks of Suicidality & Homocidality in Psychiatric Medications
Psychiatric Medication is SO MUCH More Complicated Than We're Recognizing --
That Leads to Gross Incompetence on the Clinical Front,
Many Unrecognized Injustices in the Criminal System, and
Untold Tragedies-- BUT Science Is Putting the Pieces Together
Journal of The Royal Society of Medicine (2016) Conclusions: Antidepressants double the occurrence of events in adult healthy volunteers that can lead to suicide and violence. |
Your browser does not support viewing this document. Click here to download the document.
|
Journal of Forensic and Legal Medicine (2015):
Independent Forensic Services LLC, 32796 Edward Drive, Conifer, CO, 80433, USA
Forensic Psychiatrist, Pharmacogeneticist, Suite 310, Level 3 203-223 New South Head Road, Point Piper, NSW, 2027, Australia
Department of Biological Sciences, University of Denver, Denver, CO, 80208, USA
The relevance of cytochrome P450 polymorphism in forensic medicine and akathisia-related violence and suicide
ABSTRACT |
Your browser does not support viewing this document. Click here to download the document.
|
Mental Health Advocate Amy Smith
Sounding the ALARM Regarding New Black Box Warnings for People who are "Poor or Rapid Metabolizers"
RISKS INCLUDE --- SUICIDE & HOMICIDALITY
Amy Smith:
"Well, we DO have a handle on one specific problem and that is the See 2.7 on p.7 of Abilify Prescribing Information:
Dosage Adjustments for Cytochrome P450 Considerations Dose Adjustments for ABILIFY in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducer From the US Food & Drug Administration (FDA) -- Abilify's 84-page Prescribing Information, including the "Black Box" warning -- see p. 47 >>>>>>
8.6 CYP2D6 Poor Metabolizers Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole [Brand names -- Abilify, Abilify Maintena, and Aristada] concentrations. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM) [see DOSAGE AND ADMINISTRATION (2.7) and CLINICAL PHARMACOLOGY (12.3)]. |
|